Skip to main content

Table 1 Clinical characteristics of the CPFE patients

From: Use of machine learning models to predict prognosis of combined pulmonary fibrosis and emphysema in a Chinese population

Variable

All patients (n = 184)

Deceased patients (n = 90)

Surviving patients (n = 94)

P value*

Age, y

66.8 ± 10.5

69.4 ± 9.2

64.2 ± 11.0

0.001

Sex, n (%)

Male

143 (77.7)

71 (78.9)

72 (76.6)

0.709

Female

41 (22.3)

19 (21.1)

22 (23.4)

 

BMI, kg/m2

23.6 (21.5, 25.6)

23.4 (21.4, 25.0)

23.7 (21.5, 26.0)

0.379

Smoking, n (%)

105 (57.1)

51 (56.7)

54 (57.5)

0.915

Comorbidities, n (%)

Pulmonary hypertension

48 (26.1)

33 (36.7)

15 (16.0)

0.001

Lung cancer

6 (3.3)

6 (6.7)

0 (0.0)

0.033

Baseline lung function

FEV1, %Predicted

82.8 (72.4, 90.0)

82.3 (71.5, 87.9)

84.0 (73.5, 96.1)

0.099

FVC, %Predicted

84.0 (72.4, 91.1)

82.9 (66.0, 89.1)

86.1 (74.8, 96.4)

0.025

FEV1/FVC, %

77.9 (71.0, 85.3)

78.0 (72.8, 83.7)

77.9 (68.5, 85.7)

0.574

TLC, %Predicted

74.2 (66.4, 80.3)

73.1 (63.8, 78.4)

74.6 (68.5, 83.0)

0.034

DLCO, %Predicted

44.0 (36.0, 52.1)

40.3 (27.0, 47.2)

46.7 (40.7, 58.6)

 < 0.001

Echocardiography

RAA, cm2

14.0 ± 3.6

14.5 ± 4.5

13.7 ± 2.4

0.135

RVD, mm

17.3 ± 3.3

18.5 ± 4.0

16.1 ± 1.8

 < 0.001

LVEF, %

63.0 (61.0, 64.0)

62.0 (60.0, 64.0)

63.1 (61.8, 65.0)

0.027

Image of HRCT, n (%)

Fine reticular opacity

94 (51.1)

50 (55.6)

44 (46.8)

0.235

Ground-glass opacity

15 (8.2)

7 (7.8)

8 (8.5)

0.856

Patchy shadow

89 (48.4)

47 (52.2)

42 (44.7)

0.306

Traction bronchiectasis

16 (8.7)

6 (6.7)

10 (10.6)

0.339

Honeycomb shadow

43 (23.4)

23 (25.6)

20 (21.3)

0.493

Local pleural thickening

146 (79.3)

76 (84.4)

70 (74.5)

0.095

Mediastinal lymphadenopathy

115 (62.5)

64 (71.1)

51 (54.3)

0.018

KL-6, U/ml

1201.6 (830.0, 1263.8)

1217.9 (1095.8, 1296.4)

1175.5 (696.5, 1262.0)

0.028

CYFRA21-1, ng/ml

3.8 (2.3, 5.7)

4.2 (2.7, 6.4)

3.0 (2.1, 5.3)

0.015

Treatment, n (%)

Pirfenidone

76 (41.3)

36 (40.0)

40 (42.6)

0.725

Glucocorticoids

86 (46.7)

46 (51.1)

40 (42.6)

0.245

Acetylcysteine

118 (64.1)

51 (56.7)

67 (71.3)

0.039

Immunosuppressive agents

27 (14.7)

15 (16.7)

12 (12.8)

0.455

Follow-up time, months

16.9 (6.7, 33.3)

9.4 (2.3, 21.7)

21.0 (13.2, 38.6)

 < 0.001

  1. CPFE combined pulmonary fibrosis and emphysema; mean ± SD mean ± standard deviation; BMI body mass index; IQR interquartile range; FEV1 forced expiratory volume in the first second; FVC forced vital capacity; FEV1/FVC the ratio of FEV1 to FVC; TLC total lung capacity; DLCO diffusing lung capacity for carbon monoxide; RAA right atrial area; RVD right ventricular diameter; LVEF left ventricular ejection fraction; HRCT high-resolution computed tomography; KL-6 Krebs von den Lungen-6; CYFRA21-1 cytokeratin-19-fragment
  2. *Comparison of the performance of the deceased patients and the surviving patients for clinical characteristics
  3. Data were presented as the means ± SDs, numbers (%) or medians (IQR)
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us